Will Post-COVID Stress Spike Demand for Benzodiazepine Drugs? New Study Explores

Award winning market research firm Fact.MR projects the global benzodiazepine drugs market to expand gradually, registering moderate growth through 2021.

Heightening demand for quality branded drugs to widen growth frontiers, albeit at low value projections in the future.

Award winning market research firm Fact.MR projects the global benzodiazepine drugs market to expand gradually, registering moderate growth through 2021. Analysis predicts the landscape to experience a modest yet positive expansion trajectory in the next 10 years as anxiety levels peak amid heightened stress levels across all countries.

The United States is expected to remain a key growth stimulator. According to the National Center for Health Statistics, approximately 66 million benzodiazepine prescriptions are written by doctors annually across the US, thus prompting manufacturers to adopt a slew of intricate drug formulations to dole out highly effective doses of different categories of drugs. Fact.MR thus projects heightened investments across the region.

In addition, a robust pharmaceutical industry has rendered India a potential cash cow for the benzodiazepine drugs market in recent years. Globally, India accounts for one-fifth of generic medicines exports while 21% of revenue generation happens from the patented drugs segment. Naturally, manufacturers are scrambling to acquire lucrative revenue shares across the country, thus widening development prospects across the South Asian market.

“Stringent regulatory frameworks to prevent overdose across developed regions are prompting manufacturers to foray into emerging economies, mostly across the Asia-Pacific, leading to substantial expansion opportunities across these regions and shifting the revenue landscape,” comments the Fact.MR analyst.

Request a report sample with 170 pages to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4432

Key Takeaways from Fact.MR’s Benzodiazepine Drugs Report

  • Short acting benzodiazepine drugs to account for over seven out of ten sales in the wake of faster throughput results
  • Heightened stress levels amongst individuals due to sedentary lifestyle prevalence to enhance anti-anxiety applications
  • By distribution channel, hospital pharmacies are likely to remain dominant, attributed to clampdown on illicit OTC drug exchanges
  • Alprazolam benzodiazepine drugs to account for maximum sales across the forecast period
  • U.K to generate over a fifth of the total benzodiazepine drugs revenue in the long-run
  • Japan to gain high ground amid introduction of designer benzodiazepine formulations
  • South Korea to be an attractive hotspot, given the high prevalence rate of insomnia amongst the geriatric population

Benzodiazepine Drugs- Prominent Drivers

  • High prevalence of insomnia and anxiety disorders due to sedentary lifestyles to widen the berth for benzodiazepine drugs sales
  • Opportunities abound in the generic and branded drugs categories

Benzodiazepine Drugs- Key Restraints

  • Heightened abuse and overdose is compelling governments across developed regions to restrict OTC sales, thus hindering growth prospects

Discover more about the global benzodiazepine market with 93 figures and 30 data tables, along with the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4432/benzodiazepine-drugs-market

Competitive Landscape

Prominent benzodiazepine drug manufacturers profiled in Fact.MR’s report include Pfizer Inc., Aurobindo Pharma, Apotex Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals Ltd., F. Hoffman La-Roche Ltd., Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and H. Lundbeck A/S. The aforementioned players operate in a highly competitive environment, compelling them to adopt a slew of expansion strategies.

For instance, pharmaceutical giant Pfizer Inc. has announced a major revamp in its biotechnology innovation segment through the Pfizer Breakthrough Growth Initiative (PBGI). Through this, the company plans to invest upto US$ 500 million in biotechnology companies to ensure continuity of clinical development programs. This is expected to provide a major boost to benzodiazepine drug development initiatives as well.

Also, in January 2021, Amneal Pharmaceuticals announced the complete acquisition of Kashiv Specialty Pharmaceuticals, part and parcel of Amneal’s 2.0 growth strategy. Additionally, this transaction is expected to enhance its R&D expertise for developing complex generic products and innovative drug delivery technologies.

More Insights on Fact.MR’s Benzodiazepine Drugs Market

In the report by Fact.MR, we offer an unbiased analysis of the global benzodiazepine drugs market. In order to understand the global market potential, its growth and scopes, the market is segmented on the basis of distribution channel (hospital pharmacies, retail pharmacies and others), time of action (ultra-short acting, short acting & long acting), application (anxiety, seizures, insomnia, alcohol withdrawal & others) and product (alprazolam, clonazepam, diazepam, lorazepam & others) across five key regions.

Explore Fact.MR’s Coverage on the Healthcare Division

Biobanking Market: Fact.MR’s extensive coverage on the global biobanking market brings to the fore credible insights about the potential drivers, opportunities, trends and restraints associated with future proliferation across the assessment period ranging from 2020-2027. Readers can avail qualitative and quantitative data regarding key developments across prominent segments spread over five key geographies.

Home Diagnostics Market: A recent study by Fact.MR on the home diagnostics market offers a 10-year forecast for 2020 to 2030. The study analyzes crucial trends that are currently determining the growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders. The study also provides the dynamics that are responsible for influencing the future status of the market over the forecast period.

Foot Orthotic Insoles Market: Fact.MR recently published a market study on the global market for foot orthotic insoles. The study provides detailed assessment of the market background and market dynamics, including the drivers, trends, opportunities restraints, and detailed information about the foot orthotic insoles market structure. The market study presents exclusive information about how the foot orthotic insoles market will grow during the forecast period (2020-2030).

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, Ireland, and has delivery centers in the U.S. and India. Fact.MR’s latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates